Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis

Marina Romozzi; Matteo Palermo; Daisuke Danno; Masahito Katsuki; Federico Tosto; Francesco Signorelli; Marina Romozzi; Yasuhiko Matsumori; Paolo Calabresi; Ilaria Frattale; Luigi Francesco Iannone

doi:10.1186/s10194-026-02283-5

January 30, 2026The Journal of Headache and PainOpen Access

Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis

View Full Paper

Ask AI

Bookmark

Share

Key Points

Anti-CGRP monoclonal antibodies improve outcomes in hemiplegic migraine.
Quantitative analysis of individual patients highlights significant benefits in migraine frequency.
Longitudinal data indicates sustained effectiveness and safety over time.
Findings suggest a viable treatment option for individuals suffering from hemiplegic migraine.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Individual patient quantitative analysis shows effectiveness of anti-CGRP monoclonal antibodies in hemiplegic migraine, suggesting a beneficial intervention.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Romozzi et al. (2026) studied this question.

synapsesocial.com/papers/69a75f8fc6e9836116a2b040 https://doi.org/10.1186/s10194-026-02283-5

View Full Paper

Ask AI

Bookmark

Share

Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading